Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 6/2008

01-06-2008 | Brief Report

Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis

Authors: John Serelis, Meropi D. Kontogianni, Stergios Katsiougiannis, Maria Bletsa, Maria G. Tektonidou, Fotini N. Skopouli

Published in: Clinical Rheumatology | Issue 6/2008

Login to get access

Abstract

The aim of this study was to investigate the effect of anti-tumor necrosis factor alpha (anti-TNF) treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis (RA). Nineteen women with RA starting anti-TNF treatment were included in the study. Disease activity, body composition, lumbar spine bone mineral density (BMD) and serum adiponectin concentrations were measured at baseline and after 1 year of follow-up. No important changes on body composition and lumbar spine BMD were observed, while the serum levels of adiponectin levels increased after 1 year of anti-TNF treatment (p = 0.02). Anti-TNF treatment in women with RA does not have any significant effect on body composition; however, it is associated with increase in adiponectin levels which may ameliorate the systemic inflammatory response state associated with RA.
Literature
1.
Westhovens R, Nijs J, Taelman V et al (1997) Body composition in rheumatoid srthritis. Br J Rheumatol 36:448–448 AprCrossRef
2.
Munro R, Capell H (1997) Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis 56:326–329PubMed
3.
Roubenoff R, Roubenoff RA, Cannon JG et al (1994) Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 93:2379–2386PubMedCrossRef
4.
Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMedCrossRef
5.
Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295PubMedCrossRef
6.
Kontogianni MD, Dafni UG, Routsias JG et al (2004) Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546–551PubMedCrossRef
7.
Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRef
8.
Hector J, Schwarzloh B, Goehring J et al (2007) TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 39:250–255PubMedCrossRef
9.
Shioji K, Moriwaki S, Takeuchi Y et al (2007) Relationship of serum adiponectin to level of adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ J 71:675–680PubMedCrossRef
10.
Stefan N, Ehling A, Neumann E et al (2003) Adipocytokines in synovial fluid. JAMA 290:1709–1710CrossRef
11.
Ehling A, Schäffler A, Herfarth H et al (2006) The potential of adiponectin in driving arthritis. J Immunol 176:4468–4478PubMed
12.
van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850PubMedCrossRef
13.
Vis M, Havaardsholm EA, Haugeberg G et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and rankl serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499PubMedCrossRef
14.
Marcora SM, Chester KR, Mittal G et al (2006) Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84:1463–1472PubMed
15.
Harle P, Sarzi-Puttini P, Cutolo M et al (2006) No change of serum levels of leptin and adiponectin during anti-tumor necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 65:970–971PubMedCrossRef
16.
Komai N, Morita Y, Sakuta T et al (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17:385–390PubMedCrossRef
17.
Otero M, Lago R, Gomez R et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65:1198–1201PubMedCrossRef
18.
Senolt L, Pavelka K, Housa D et al (2007) Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 38:151–156PubMedCrossRef
Metadata
Title
Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis
Authors
John Serelis
Meropi D. Kontogianni
Stergios Katsiougiannis
Maria Bletsa
Maria G. Tektonidou
Fotini N. Skopouli
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-0855-7

Other articles of this Issue 6/2008

Clinical Rheumatology 6/2008 Go to the issue

Brief Report

The significance of platelet activation in ankylosing spondylitis

Case Report

A case of atypical giant cell arteritis diagnosed by positron emission tomography (PET)

Brief Report

Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis

Case Report

Bisphosphonate treatment in craniofacial fibrous dysplasia—a case report and review of the literature

Brief Report

The diagnostic accuracy of power Doppler ultrasonography for differentiating secondary from primary Raynaud’s phenomenon in undifferentiated connective tissue disease

Brief Report

Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits